Global expansion Sanovel aims to become a global pharmaceutical company with EU GMP certification and FDA approval, presenting opportunities to propose international distribution partnerships, contract manufacturing, and cross-border licensing arrangements.

R&D and IP moat With a strong R&D focus and leadership in intellectual property, there is potential to pitch collaborative development programs, licensing of patented compounds, and co-development deals for new formulations or biosimilar equivalents.

Extensive portfolio Over 60 brands and 180 products across multiple therapeutic areas creates cross-sell and line-extension opportunities, as well as coordinated sales strategies for hospitals, clinics, and wholesalers.

Strategic partnerships Past licensing activity with PharmaMar indicates openness to partnerships; approach them with options for licensing, exclusive distribution, or joint ventures in oncology and marine-derived therapeutics.

Scale and capability Large production capacity and certified facilities enable discussions around contract manufacturing, private-label programs, and supply-chain collaborations to support new market entries and large-volume orders.